AIMS: The aim of this experiment was to determine the influence of acute bupropion pre-treatment on subject-rated effects and choice of intranasal cocaine versus money. DESIGN: A randomized, within-subject, placebo-controlled, double-blind experiment. SETTING: An out-patient research unit. PARTICIPANTS: Eight cocaine-using adults. MEASUREMENTS: Subjects completed nine experimental sessions in which they were pre-treated with 0, 100 or 200 mg oral immediate release bupropion. Ninety minutes later they sampled an intranasal cocaine dose [4 (placebo), 15 or 45 mg] and made six choices between that dose and an alternative reinforcer (US$0.25), available on independent, concurrent progressive ratio schedules. Subjects also completed a battery of subject-rated, performance and physiological measures following the sample doses of cocaine. FINDINGS: After 0 mg bupropion, the high dose of cocaine (45 mg) was chosen five of six times on average compared to 2.25 of six choices for placebo cocaine (4 mg) (P < 0.05). Active bupropion reduced choice of 45 mg cocaine to 3.13 (100 mg) or 4.00 (200 mg) out of six drug choices on average. Bupropion also consistently enhanced positive subject-rated effects of cocaine (e.g. good effects; willing to take again) while having no effects of its own. CONCLUSIONS: The atypical antidepressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug.
RCT Entities:
AIMS: The aim of this experiment was to determine the influence of acute bupropion pre-treatment on subject-rated effects and choice of intranasal cocaine versus money. DESIGN: A randomized, within-subject, placebo-controlled, double-blind experiment. SETTING: An out-patient research unit. PARTICIPANTS: Eight cocaine-using adults. MEASUREMENTS: Subjects completed nine experimental sessions in which they were pre-treated with 0, 100 or 200 mg oral immediate release bupropion. Ninety minutes later they sampled an intranasal cocaine dose [4 (placebo), 15 or 45 mg] and made six choices between that dose and an alternative reinforcer (US$0.25), available on independent, concurrent progressive ratio schedules. Subjects also completed a battery of subject-rated, performance and physiological measures following the sample doses of cocaine. FINDINGS: After 0 mg bupropion, the high dose of cocaine (45 mg) was chosen five of six times on average compared to 2.25 of six choices for placebo cocaine (4 mg) (P < 0.05). Active bupropion reduced choice of 45 mg cocaine to 3.13 (100 mg) or 4.00 (200 mg) out of six drug choices on average. Bupropion also consistently enhanced positive subject-rated effects of cocaine (e.g. good effects; willing to take again) while having no effects of its own. CONCLUSIONS: The atypical antidepressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug.
Authors: Carl L Hart; Margaret Haney; Suzanne K Vosburg; Eric Rubin; Richard W Foltin Journal: Neuropsychopharmacology Date: 2007-06-13 Impact factor: 7.853
Authors: F Gerard Moeller; Joy M Schmitz; Joel L Steinberg; Charles M Green; Christopher Reist; Lingo Y Lai; Alan C Swann; John Grabowski Journal: Am J Drug Alcohol Abuse Date: 2007 Impact factor: 3.829
Authors: James Poling; Alison Oliveto; Nancy Petry; Mehmet Sofuoglu; Kishorchandra Gonsai; Gerardo Gonzalez; Bridget Martell; Thomas R Kosten Journal: Arch Gen Psychiatry Date: 2006-02
Authors: Steve Shoptaw; Keith G Heinzerling; Erin Rotheram-Fuller; Uyen H Kao; Pin-Chieh Wang; Michelle A Bholat; Walter Ling Journal: J Addict Dis Date: 2008
Authors: William W Stoops; Justin C Strickland; Lon R Hays; Abner O Rayapati; Joshua A Lile; Craig R Rush Journal: Psychopharmacology (Berl) Date: 2016-03-01 Impact factor: 4.530
Authors: Amy R Johnson; Matthew L Banks; Bruce E Blough; Joshua A Lile; Katherine L Nicholson; S Stevens Negus Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492